期刊文献+

胰腺癌患者血浆溶血磷脂酸的临床意义

Clinical significance of plasma lysophosphatidic acid in pancreatic carcinoma patients
下载PDF
导出
摘要 目的:检测胰腺癌患者血浆溶血磷脂酸(lysphosphaticlic acid,LPA)的水平,评价LPA在胰腺癌诊治中的临床意义。方法:采用定磷法检测2006年6月至2010年10月南京第一医院收治的胰腺癌患者50例、胰腺良性疾病患者32例及健康志愿者36人的血浆LPA水平,同时测定血清CA19-9、AFP和CEA的水平;免疫组化法检测胰腺癌组织及癌旁胰腺组织LPA2受体的表达。分析血浆LPA水平与胰腺癌临床病理特征的关系。结果:胰腺癌患者血浆LPA水平明显高于胰腺良性疾病患者和健康志愿者[(4.10±2.03)vs(3.28±1.26)、(2.27±1.02)μmol/L,P<0.05],胰腺癌患者血浆LPA水平和血清CA19-9水平密切相关(r=0.9070,P<0.01)。胰腺癌组织LPA2受体表达阳性率显著高于癌旁正常胰腺组织(88%vs 4%,P<0.05)。血浆LPA水平的升高与胰腺癌浸润和淋巴结转移等相关。结论:血浆LPA检测为胰腺癌诊断和预后判断增加了一项潜在的评价指标。 Objective: To observe the levels of plasma lysophosphatidic acid(LPA) in patients with pancreatic carcinoma,and to evaluate its clinical potential of diagnosis.Methods: Plasma LPA and serum CA19-9,AFP and CEA levels were measured in 50 patients with pancreatic carcinoma and 32 patients with benign pancreatic lesions hospitalized in Nanjing First Hospital during June of 2006 and October of 2010,and 36 healthy donors by phosphate determination method.Immunohistochemistry(IHC) was used to determine the expression of LPA2 receptor both in surgically resected pancreatic carcinomas and adjacent non tumor tissues.The correlation between LPA levels with clinical pathological features of pancreatic carcinoma patients was analyzed.Results: Plasma LPA concentration was significantly higher in pancreatic carcinoma patients than in patients with benign lesions and controls([4.10±2.03] vs [3.28±1.26],[2.27±1.02] μmol/L,P0.05).Plasma LPA concentration was correlated with serum CA19-9 level(r=0.9070,P0.01) in patients with pancreatic carcinoma.The positive rate of LPA2 receptor in pancreatic carcinoma tissues was significantly higher than that in adjacent non tumor tissues(88% vs 4%,P0.05).Higher plasma LPA level showed a significant correlation with invasion and metastasis of pancreatic carcinoma.Conclusion: Plasma LPA level might be a potential indicator of the diagnosis and prognosis of pancreatic carcinoma.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2012年第2期191-195,共5页 Chinese Journal of Cancer Biotherapy
基金 江苏省卫生厅科教兴卫工程专项基金资助(苏卫科教2011字第15号) 南京市医学重点科技发展项目(No.ZKX09007)~~
关键词 胰腺癌 溶血磷脂酸 CA19-9 诊断 预后 pancreatic carcinoma lysophosphatidic acid CA19-9 diagnosis prognosis
  • 相关文献

参考文献17

  • 1Bazzi W, Renon M, Vercherat C, et al. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells [J]. Gastroenterology, 2008, 135(5) : 1698-1709.
  • 2Asma Sultana, Catrin Tudur Smith, David Cunningham, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer [J]. J Clin Oncol, 2007, 25(9) : 2607-2615.
  • 3Liu S, Umezu-Goto M, Murph M, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases [J]. Cancer Cell, 2009, 15(6) : 539-550.
  • 4Yamada T, Sato K, Komachi M, et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer ceils through LPA1 [J]. J Biol Chem, 2004, 279(8) : 6595-6605.
  • 5Lin ME, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance [ J ]. Prostaglandins Other Lipid Mediat, 2010, 91 (3/4) : 130-138.
  • 6Xu X, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model [ J ]. Cancer, 2010, 116 (7) : 1739-1750.
  • 7Gong YL, Xu GM, Huang WD, et al. Expression of matrix metalloproteinases and the tissue inhibitors ofmetalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer [J]. J Surg Oncol, 2000, 73 (2) : 95-99.
  • 8龚涌灵,Frank FANG.内皮分化基因受体介导溶血磷脂酸:肿瘤靶向治疗的新靶点[J].中国肿瘤生物治疗杂志,2011,18(6):588-596. 被引量:3
  • 9Artinyan A, Anaya DA, McKenzie S, et al. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma [J]. Cancer, 2011, 117(10): 2044-2049.
  • 10Moolenaa WH. Lysophosphatidic acid, a multifunctional phospholipid messenger [J]. J Biol Chem, 1995, 270 (22) : 12949- 12952.

二级参考文献13

  • 1杨瑞,徐宏里,夏文艳.血浆溶血磷脂酸与CA_(125)共同诊断卵巢癌价值的探讨[J].中国老年学杂志,2004,24(6):527-528. 被引量:2
  • 2Fishman DA,Liu Y, Ellerbroek SM, et al. Lysophosphatidic acid promotes matrix metallo proteinase(MMP) activation and MMP - dependent invasion in ovarian cancer cells. Cancer Res. 2001,61(7) :3194.
  • 3Pastilnik TB, Estrclla V, Wiener JR, et al. Lysophosphafidic acid induces urkinasc secretion by ovarian cancer cells. Clin Cancer Res. 1999,5(11) :3704.
  • 4Sakamoto S,Yokoyama M, Zhang X, et al. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperphsia and its regulation by lysophosphatidic acid. Endocrinology. 2004,145(6) :2929.
  • 5Shen ZZ, Bclinson J, Morton RE, et al. Phorbol 12 - myrlstate 13 - acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol. 1998,71 ( 1 ) :364.
  • 6Eder AM, Sasagawa T, Mao M, et al. Constitutive and lysophophatidic acid (LPA) induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res. 2000,6:2482.
  • 7Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA125 level. Gynecol Obstet Invest. 2004,57(3) :153.
  • 8Bast RC Jr,Xu FJ,Yu YH, et al. CA125 :the past and the future. Int J Biol Markers. 1998,13(4) :179.
  • 9Xu Y, Shen ZZ, Donald W, et al. Lysophosphatldic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998, 280(8) :719.
  • 10Hu YL,Albancse C, PestcU RG, et al. Dual mechanisms for lyso-phophatidic acid stimulation of human ovarian carcinoma cells. J Nail Cancer Inst. 2003,95(10) :733.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部